Temperature Instability in an Infant Treated with Propranolol for Infantile Hemangioma

Burkey, Betsy Walters; Jacobs, John C.; Aziz, Hany

doi:10.5863/1551-6776-22.2.124

Cited by 4 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the one hand, reports of rare AE are very important so that when the phenomenon occurs, doctors can promptly reflect that it is caused by propranolol, thus allowing timely handling of the phenomenon; on the other hand, usage of propranolol as a treatment of IHs can be improved. For example, a report of dental caries suggested that sugar-free propranolol oral solutions are recommended for children [31]; propranolol may affect thermoregulation in infants, whereas atenolol may not [32].…”

Section: Discussionmentioning

confidence: 99%

Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and Follow-Up to Age Two

Yang

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Objective To analyse the short-term adverse effects (AEs) of propranolol in the treatment of infantile hemangiomas (IHs) and their relevant factors, as well as the relationship between child growth and propranolol. Methods A total of 506 patients with confirmed or suspected IHs were enrolled, and a total of 439 cases were included in the study. Short-term AEs were analysed using single-factor analysis and binary logistic regression. Out of 439 patients, 292 were enrolled to examine the effect of propranolol on 2-year-olds' height and body weight (BW), by comparison with reference range and among groups. Spearman rank correlation analysis was used to determine the relationship between BW, height, and duration of propranolol treatment. Results Among 439 patients, 70 (16.0%) experienced AEs. Among them, 48 had gastrointestinal (GI) symptoms, 23 had central nervous system (CNS) symptoms, 8 had both symptoms above, and 7 had other symptoms. Most of the AEs occurred on the starting day (day 0), and 6 children's AEs were transient. Starting age of no older than 3 months led to more CNS symptoms, and starting age of older than 3 months was a protective factor against CNS symptoms, with an OR value of 0.303 (0.117–0.783). Height and BW of 292 two-year-old children were no less than the reference levels, although those of 3 females and 1 male were less than the average −2 standard deviation (−2SD). The height and BW of the children at the age of two was not related to the length of time of propranolol treatment. Conclusion Oral propranolol has a good tolerance in the treatment of IHs. Oral propranolol exerts more adverse effects on the CNS of lower age children, and it has exhibited no effect on the growth of two-year-old children.

show abstract

Section: Discussionmentioning

confidence: 99%

Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and Follow-Up to Age Two

Yang

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…5,9 Previous case reports have shown that use of beta blockers in neonates especially preterm neonates is associated with hypothermia. 11,12 However maternal use of labetalol and its effect on neonatal thermoregulation have not been studied extensively. Labetalol like other beta blockers has been shown to cross placenta freely.…”

Section: Discussionmentioning

confidence: 99%

Modifiable and Nonmodifiable Factors Contributing to Hypothermia Among High Risk Neonates at Admission to NICU—A Prospective Observational Study

Sharma

Rao

Pawale

et al. 2021

Journal of Neonatology

View full text Add to dashboard Cite

Background: Hypothermia is a well-known contributor to neonatal morbidity and mortality, especially for preterm and low-birth weight neonates. Identifying the predictors for admission hypothermia which are specific to the settings is important to initiate quality improvement projects and improve clinical outcomes. Methods: Study was conducted over a period of 6 months from 1 April to 31 September 2018. All inborn infants needing neonatal intensive care unit (NICU) admission were eligible for the study. The study involved measuring temperatures at exit from delivery room (DR) and at admission to NICU. Hypothermia was defined as core admission temperature <36.5°C. The data collected included all modifiable and nonmodifiable risk factors for hypothermia in newborns. Data was analyzed using logistic regression to determine associations, if any, between admission hypothermia and maternal, neonatal, and environmental characteristics. Results: One hundred and ninety-three infants were enrolled in the study. The incidence of admission hypothermia (<36.5°C) was 83.9%. Forty-four (22.8%) infants had mild hypothermia, 61.1% infants had moderate hypothermia, and none of the neonates had severe hypothermia. Nonmodifiable factors affecting admission temperature were birth weight/gestational age and mother’s temperature before shifting to DR. DR temperature strongly predicted the admission temperature and every 1°C increase in DR temperature improved the rate of admission hypothermia by 34%. Conclusion: Significant proportion of neonates is hypothermic at the time of admission to NICU. DR temperature significantly predicts hypothermia at admission in neonates needing NICU admission.

show abstract

“…The common side effects (35,47) of propranolol include gastrointestinal discomfort, sleep disorders, agitation, and body temperature fluctuations. The serious ARs reported with propranolol treatment include atrioventricular block, bradycardia, hypotension, bronchospasm/bronchial hyperresponsiveness, and hypoglycemia.…”

Section: Oral Medications Beta-adrenergic Blocking Agents (β Blockers)mentioning

confidence: 99%

Progress in the treatment of infantile hemangioma

et al. 2019

View full text Add to dashboard Cite

Infantile hemangioma (IH) is a common benign tumor, which mostly resolves spontaneously; however, children with high-risk IH need treatment. Currently, the recognized first-line treatment regimen for IH is oral propranolol, but research on the pathogenesis of IH has led to the identification of new therapeutic targets, which have shown good curative effects, providing more options for disease treatment.This article summarizes the applications of different medications, dosages, and routes of administration for the treatment of IH. In addition to drug therapy, this article also reviews current therapeutic options for IH such as laser therapy, surgical treatment, and observation. To provide the best treatment, therapeutic regimens for IH should be selected based on the child's age, the size and location of the lesion, the presence of complications, the implementation conditions, and the potential outcomes of the treatment.

show abstract

Temperature Instability in an Infant Treated with Propranolol for Infantile Hemangioma

Cited by 4 publications

References 14 publications

Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and Follow-Up to Age Two

Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and Follow-Up to Age Two

Modifiable and Nonmodifiable Factors Contributing to Hypothermia Among High Risk Neonates at Admission to NICU—A Prospective Observational Study

Progress in the treatment of infantile hemangioma

Contact Info

Product

Resources

About